Moneycontrol PRO
HomeNewsBusinessMarketsPiramal Pharma stock surges 5.5% on solid Q2 earnings show

Piramal Pharma stock surges 5.5% on solid Q2 earnings show

Strong growth in Piramal Pharma's flagship Contract Development Manufacturing (CDMO) business and improved operational performance aided the sharp surge in its bottomline.

October 24, 2024 / 09:42 IST
Piramal Pharma stock rose 37 percent in the past three months.
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Shares of Piramal Pharma soared as much as 5.5 percent in early trade on October 24, a day after the drugmaker reported solid earnings for the July-September quarter, marked by a steep surge in its net profit.

    At 09.38 am, shares of Piramal Pharma were trading at Rs 227.29 on the NSE.

    The drugmaker's net profit zoomed 3.5 times year-on-year to Rs 22.59 crore in the September quarter, up from Rs 5.02 crore in Q2 FY24.

    Piramal Pharma’s CDMO business got a boost from the growing demand for innovation-driven projects. The company also unveiled an $80 million expansion plan for its Lexington facility, set for completion by FY27, positioning itself to meet the rising need for sterile fill-finish capabilities. Sales for its CDMO business, which accounts for 59 percent of total revenue, grew 24 percent on year to Rs 1,320 crore.

    Follow our market blog to catch all the live action

    In the Consumer Healthcare (CHG) division, steady volume growth in inhalation anaesthesia products was reported across the US and Emerging Markets. Meanwhile, in its India Consumer Healthcare (ICH) segment, the company’s power brands and e-commerce sales continued their upward trend.

    Aided by these, revenue rose 17.3 percent to Rs 2,241.75 crore compared to Rs 1,911.38 crore in the same period last year. Meanwhile, lower opex also triggered sharp margin expansion in Q2. EBITDA margin swelled up 130 basis points on year to 15.2 percent in the quarter gone by.

    "We continue our momentum of delivering healthy revenue growth accompanied by year-on-year EBITDA margin expansion. This has been primarily driven by consistent growth in our Contract Development and Manufacturing Organisation (CDMO) business, which has witnessed a good pick-up in innovation-related work and on-patent commercial revenues," Nandini Piramal, Chairperson of Piramal Pharma said in an exchange filing.

    "Over the long term, we remain committed to achieving our financial goals of US$2 billion in revenue with a 25 percent EBITDA margin and 1x net debt/EBITDA by FY30," Piramal further guided.

    Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

    Moneycontrol News
    first published: Oct 24, 2024 09:42 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347